2-(9-anthryl)ethylamine | 398146-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 2-(9-anthryl)ethylamine
• 英文别名: 9-(2-aminoethyl)anthracene；2-Anthracen-9-yl-ethylamine；2-anthracen-9-ylethanamine
• CAS: 398146-53-7
• 化学式: C₁₆H₁₅N
• 分子量: 221.302
• InChiKey: QQALHCFUHQWZJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(9-anthryl)ethylamine 在 氨 、 sodium 作用下， 生成 2-(9,10-Dihydro-anthracen-9-yl)-ethylamine
  参考文献：
  名称：

  Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene

  摘要：

  Comparison of the serotonin 5-HT2A receptor affinities of chain lengthened and N-alkylated analogues of the novel ligand 9-aminomethyl-9,10-dihydroanthracene (AMDA) and a structurally similar prototypical tricyclic amine imipramine suggests that the two agents bind to the receptor in different fashions. The demonstration that AMDA is highly selective for serotonin receptors (5-HT2A, K-i = 20 nM; 5-HT2c, K-i = 43 nM) versus the dopamine D-2 receptor (K-i >10,000 nM), as well as the serotonin and norepinephrine transporters (Ki >10,000 nM) further suggests that AMDA and the nonselective ligand imipramine interact with these target macromolecules in different ways. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00023-3
• 作为产物：
  描述：

  trans-1-(9-anthryl)-2-nitroethylene 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-(9-anthryl)ethylamine
  参考文献：
  名称：

  Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene

  摘要：

  Comparison of the serotonin 5-HT2A receptor affinities of chain lengthened and N-alkylated analogues of the novel ligand 9-aminomethyl-9,10-dihydroanthracene (AMDA) and a structurally similar prototypical tricyclic amine imipramine suggests that the two agents bind to the receptor in different fashions. The demonstration that AMDA is highly selective for serotonin receptors (5-HT2A, K-i = 20 nM; 5-HT2c, K-i = 43 nM) versus the dopamine D-2 receptor (K-i >10,000 nM), as well as the serotonin and norepinephrine transporters (Ki >10,000 nM) further suggests that AMDA and the nonselective ligand imipramine interact with these target macromolecules in different ways. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00023-3

文献信息

• N-Substituent Effects in the Selective Delivery of Polyamine Conjugates into Cells Containing Active Polyamine Transporters
  作者：Richard Andrew Gardner、Jean-Guy Delcros、Fanta Konate、Fred Breitbeil、Bénédicte Martin、Michael Sigman、Min Huang、Phanstiel

  DOI：10.1021/jm0497040

  日期：2004.11.1

  N(1)-anthracen-9-ylmethyl, N(1)-2-(anthracen-9-yl)ethyl, N(1)-3-(anthracen-9-yl)propyl, and pyren-1-ylmethyl. The polyamine architecture was also altered and ranged from diamine to triamine and tetraamine systems. Biological activities in L1210 (murine leukemia), Chinese hamster ovary (CHO), and CHO's polyamine transport-deficient mutant (CHO-MG) cell lines were investigated via IC(50) cytotoxicity determinations

  合成了几种含有各种芳环系统的N（1）-芳基烷基多胺作为它们各自的HCl盐。评估的N（1）取代基大小从N（1）-苄基，N（1）-萘-1-基甲基，N（1）-2-（萘-1-基）乙基，N（1） -3-（萘-1-基）丙基，N（1）-蒽-9-基甲基，N（1）-2-（蒽-9-基）乙基，N（1）-3-（蒽-9 -基）丙基和pyr-1-基甲基。多胺的结构也被改变，范围从二胺到三胺和四胺体系。通过IC（50）细胞毒性测定研究了L1210（鼠白血病），中国仓鼠卵巢（CHO）和CHO的多胺转运缺陷型突变体（CHO-MG）细胞系的生物学活性。L1210细胞中亚精胺摄取的K（i）值也已确定。N（1）-芳基烷基取代基的大小以及所用的多胺序列直接影响到观察到的细胞毒性谱。如CHO / CHO-MG细胞毒性筛选所示，比乙烯长的N（1）-系链显示出对多胺转运蛋白（PAT）的选择性显着丧失。总之，对于N（1）取代基的大小有明确
• Methods for preparing arene-BIS (dicarboximide)-based semiconducting materials and related intermediates for preparing same
  申请人：Facchetti Antonio

  公开号：US20080177073A1

  公开（公告）日：2008-07-24

  The present teachings provide compounds of formulae I and II: where Q, R a , R 1 , W, and n are as defined herein. The present teachings also provide methods of preparing compounds of formulae I and II, including methods of preparing compounds of formula II from compounds of formula I. The compounds disclosed herein can be used to prepare semiconductor materials and related composites and electronic devices.

  本教学提供了符合以下公式I和II的化合物：其中Q、Ra、R1、W和n的定义如本文所述。本教学还提供了制备符合公式I和II的化合物的方法，包括从符合公式I的化合物制备符合公式II的方法。本文披露的化合物可用于制备半导体材料、相关复合材料和电子器件。
• Organic semiconductor materials and precursors thereof
  申请人：Facchetti Antonio

  公开号：US20080249309A1

  公开（公告）日：2008-10-09

  The present teachings provide novel organic semiconductor compounds and their soluble precursors, methods for preparing these compounds and precursors, as well as compositions, materials, articles, structures, and devices that incorporate such compounds.

  本教学提供了新型有机半导体化合物及其可溶性前体，制备这些化合物和前体的方法，以及包含这些化合物的组合物、材料、文章、结构和设备。
• ELECTROCHEMICAL SENSORS
  申请人：Kahn Carolyn R.

  公开号：US20140042026A1

  公开（公告）日：2014-02-13

  Systems and methods are provided for detecting the presence of an analyte in a sample. A solid state electrochemical sensor can include a redox active moiety having an oxidation and/or reduction potential that is sensitive to the presence of an analyte immobilized over a surface of a working electrode. A redox active moiety having an oxidation and/or reduction potential that is insensitive to the presence of the analyte can be used for reference. Voltammetric measurements made using such systems can accurately determine the presence and/or concentration of the analyte in the sample. The solid state electrochemical sensor can be robust and not require calibration or re-calibration.

  本发明提供了用于检测样品中分析物存在的系统和方法。固态电化学传感器可以包括一个氧化和/或还原电位对分析物存在敏感的氧化还原活性部分，该部分固定在工作电极表面上。可以使用一个对分析物存在不敏感的具有氧化和/或还原电位的氧化还原活性部分作为参考。使用这种系统进行伏安测量可以准确地确定样品中分析物的存在和/或浓度。固态电化学传感器可以坚固耐用，不需要校准或重新校准。
• NANOPARTICLES FOR DRUG DELIVERY
  申请人：KNIPP Ralph J.

  公开号：US20150374849A1

  公开（公告）日：2015-12-31

  The invention provides nanoparticles, methods for making nanoparticles, and methods for using nanoparticles. An important attribute of a drug delivery system is its ability to allow for spatial and temporal regulated drug release, thereby minimizing side effects and improving therapeutic efficacy of conventional pharmaceuticals. Iron oxide nanoparticles (NPs), specifically Fe304 nanoparticles, possess many appropriate qualities that make them a viable choice for drug delivery.

  本发明提供了纳米颗粒、制备纳米颗粒的方法以及使用纳米颗粒的方法。药物输送系统的一个重要属性是其能够允许空间和时间调节药物释放，从而最大限度地减少副作用并提高传统药物的治疗效果。铁氧化物纳米颗粒（NPs），特别是Fe304纳米颗粒，具有许多适当的特性，使它们成为药物输送的可行选择。